Imago’s core team comprises a small and unique set of individuals from the academic, biotechnology and pharmaceutical worlds who together have the capacity to identify diseases in want of new treatments and deliver a medicine from the bench to the bedside. With combined industry experience upwards of 60 years in settings varying from biotechnology to large pharma, our core team has significant breadth and depth of knowledge within chemical and clinical development, and has worked on multiple successful filings from INDs to NDAs.
Imago’s business model allows the team to leverage their drug development experience, which includes all aspects of clinical trial conduct in more than 25 countries in multiple disease areas, notably hematology and oncology, with the utilization of vendors and consultants to enhance and accelerate operations. The team works nimbly and innovatively, and with a strong focus on working collaboratively with Investigators to ensure a strong scientific foundation that translates to maximum benefit for patients, implementing new ideas and strategies swiftly.
Within Imago exists the expertise in each stage of the drug development process with the added advantage of having worked together previously as a team on successful development programs.
Imago’s business model allows the team to leverage their drug development experience, which includes all aspects of clinical trial conduct in more than 25 countries in multiple disease areas, notably hematology and oncology, with the utilization of vendors and consultants to enhance and accelerate operations. The team works nimbly and innovatively, and with a strong focus on working collaboratively with Investigators to ensure a strong scientific foundation that translates to maximum benefit for patients, implementing new ideas and strategies swiftly.
Within Imago exists the expertise in each stage of the drug development process with the added advantage of having worked together previously as a team on successful development programs.
Location: United Kingdom, Wales, Magor
Employees: 11-50
Phone: (415) 529-5055
Total raised: $146.5M
Founded date: 2012
Investors 3
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
| - | MRL Ventur... | mrlv.com |
| 25.10.2022 | MBC BioLab... | mbcbiolabs... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.11.2020 | - | $80M | - |
| 21.03.2019 | Series B | $40M | - |
| 31.10.2014 | Series A | $26.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 21.07.2021 | Imago BioSciences, Inc. : Announces Closing of $134.4 Million Initial Public Offering | Imago BioSciences, Inc. (“Imago”) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the closing of $134.4 million in gross proceeds... |
| 19.11.2020 | Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders | The drug works by inhibiting an enzyme called lysine-specific demethylase, or LSD1, which plays a role in the progression of the diseases for which bomedemstat is indicated The Food and Drug Administration has given bomedemstat breakthrough... |
| 19.11.2020 | Imago BioSciences raises $80M to advance blood cancer therapy | Patients diagnosed with myeloproliferative neoplasm, a group of blood cancers in which the body overproduces red or white blood cells, don’t have great options. Treatment tends to be palliative, without changing the course of disease. Enter... |
| 22.03.2019 | Daily funding roundup - March 22nd, 2019 | AnyMind raised $8M; Evol Technologies raised $10M; Songtradr raised $12M AnyMind: AnyMind is an app that can be installed on any website as a widget, enabling pay-per-second video and audio consultations. AnyMind has raised $8 million in ne... |
| 22.03.2019 | Term Sheet — Friday, March 22 | BILLION DOLLAR STATUS Rent the Runway reached “unicorn” status yesterday, meaning the company is now valued at more than $1 billion. The online clothing rental service raised $125 million in venture funding from investors including Franklin... |
| 21.03.2019 | Imago BioSciences Secures $40M | SAN FRANCISCO, CA, Imago BioSciences today announced a $40 million Series B financing led by Omega Funds. >> Click here for more funding data on Imago BioSciences >> To export Imago BioSciences funding data to PDF and Excel,... |
| 21.03.2019 | Imago BioSciences Raises $40M in Series B Financing | Imago BioSciences, Inc., a San Francisco, CA-based clinical-stage biotechnology company developing innovative treatments for myeloid diseases, raised $40m in Series B financing. The round was led by Omega Funds, with participation from exis... |
| 21.03.2019 | Greenspring Associates Joins $40M Series B for Imago Biosciences | SAN FRANCISCO–(BUSINESS WIRE)–Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced a $40 million Series B financing led by Omega Funds, a leading internationa... |
| 31.10.2014 | Imago BioSciences Raises $26.5M in Series A Financing | Imago BioSciences, Inc., a San Francisco, CA-based biotech company developing innovative therapeutics, raised $26.5m in Series A financing. The round was led by Clarus Ventures with participation from Frazier Healthcare, Amgen Ventures, and... |
| 31.10.2014 | Imago BioSciences Lands $26.5M in Series A | SAN FRANCISCO, CA, Biotech company developing innovative therapeutics, today announced a $26.5 million Series A financing led by Clarus Ventures. >> Click here for more funding data on Imago BioSciences >> To export Imago Bi... |
Show more